Live
- I am a victim of chit fund scam too: Majhi
- Telangana’s Ganapathi Self-Help Group Emerges Winner at PepsiCo India’s RevolutioNari Awards 2024
- Karnataka State real estate body faces problems over fine collection from builders
- ‘Mother India’ Shefali Shah goes river rafting in Rishikesh
- Hotlines meant for cybercrimes not going through in Bengaluru
- Police appeals to public to stay alert against ‘digital arrest’ scam
- Coastal enthusiasts rejoice as govt announces funding for Kambala
- A Year of Olympic heartbreak for badminton
- KSRTC rolls out 20 ‘Ambaari Utsav’ sleeper buses
- Consecutive Olympic medals, Sreejesh, HIL make headlines
Dr Reddy's announces commercial launch of 2-DG
Dr Reddy's announces commercial launch of 2-DG (Twitter)
Dr. Reddys, a leading multinational pharmaceutical company today announced the commercial launch of 2-deoxy-D-glucose (2-DG).
Dr. Reddys, a leading multinational pharmaceutical company today announced the commercial launch of 2-deoxy-D-glucose (2-DG). Dr. Reddy's will supply to major Government as well as private hospitals across the country.
In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the other parts of the country.
Dr Reddy's today tweeted, "Dr. Reddy's announces the commercial launch of 2DGâ„¢."
The 2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions. Enquiries for 2DGTM can be sent to [email protected].
2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's. 2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.
Dr. G. Satheesh Reddy, Secretary Department of Defence (R&D) and Chairman, DRDO said: "We are pleased to have worked closely with our long-term industry partner Dr. Reddy's Laboratories, Hyderabad, for testing 2-DG as a therapeutic application in the treatment of COVID-19 patients. DRDO has been contributing in the fight against COVID-19 pandemic with its spin-off technologies."
Satish Reddy, Chairman, Dr. Reddy's said: "2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic."
